For the quarter ending 2025-11-30, LEXX has $6,050,807 in assets. $1,527,353 in debts.
| Balance Sheets | 2025-11-30 | 2025-08-31 | ||
|---|---|---|---|---|
| Cash | 4,281,233 | 1,802,123 | ||
| Short-term investments | 143,267 | 143,267 | ||
| Marketable securities | 0 | 22,093 | ||
| Accounts receivable | 88,044 | 368,358 | ||
| Prepaid expenses and other current assets | 850,585 | 1,132,504 | ||
| Total current assets | 5,363,129 | 3,468,345 | ||
| Long-term receivables | 64,013 | 64,013 | ||
| Right of use assets | 99,485 | 106,816 | ||
| Intellectual property, net | 308,060 | 307,818 | ||
| Property & equipment, net | 216,120 | 228,129 | ||
| Total non-current assets | 687,678 | 706,776 | ||
| Total assets | 6,050,807 | 4,175,121 | ||
| Accounts payable and accrued liabilities | 1,425,433 | 1,463,046 | ||
| Deferred revenue | - | 0 | ||
| Lease liability, current | 31,101 | 30,417 | ||
| Total current liabilities | 1,456,534 | 1,493,463 | ||
| Lease liabilities - non-current | 70,819 | 78,903 | ||
| Total liabilities | 1,527,353 | 1,572,366 | ||
| Share capital authorized 220,000,000 common voting shares with a par value of 0.001 per share common shares issued and outstanding 22,225,846 and 19,559,179 at november 30, 2025 and august 31, 2025, respectively | 22,226 | 19,559 | ||
| Additional paid-in capital | 70,022,365 | 66,501,086 | ||
| Accumulated deficit | -65,055,620 | -63,460,613 | ||
| Accumulated other comprehensive loss | -76,079 | -70,335 | ||
| Equity attributable to shareholders of lexaria | 4,912,892 | 2,989,697 | ||
| Non-controlling interest | -389,438 | -386,942 | ||
| Total stockholders' equity | 4,523,454 | 2,602,755 | ||
| Total liabilities and stockholders' equity | 6,050,807 | 4,175,121 | ||
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)